Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clini. 2024;74(3):229–63.

Article  Google Scholar 

Cui Y, Mubarik S, Li R, Yu C. Trend dynamics of thyroid cancer incidence among China and the US adult population from 1990 to 2017: a joinpoint and age-period-cohort analysis. BMC Public Health. 2021;21(1):1–13.

Article  Google Scholar 

Lee HK, Noh MH, Hong SW, Kim SM, Kim SH, Kim YS, Broaddus VC, Hur DY. Erlotinib activates different cell death pathways in EGFR-mutant lung cancer cells grown in 3D versus 2D culture systems. Anticancer Res. 2021;41(3):1261–9.

Article  CAS  PubMed  Google Scholar 

Lorusso L, Cappagli V, Valerio L, Giani C, Viola D, Puleo L, Gambale C, Minaldi E, Campopiano MC, Matrone A. Thyroid cancers: from surgery to current and future systemic therapies through their molecular identities. Int J Mol Sci. 2021;22(6):3117.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Avram AM. Radioiodine theranostics of differentiated thyroid carcinoma. In: Integrated diagnostics and theranostics of thyroid diseases. Cham: Springer International Publishing; 2023. p. 111–27.

Chapter  Google Scholar 

Yu Q, Zhang X, Li L, Zhang C, Huang J, Huang W. Molecular basis and targeted therapies for radioiodine refractory thyroid cancer. Asia Pac J Clin Oncol. 2023;19(3):279–89.

Article  PubMed  Google Scholar 

Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, Lorusso L, Cappagli V, Pieruzzi L, Giani C. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer. 2016;23(4):R185-205.

Article  CAS  PubMed  Google Scholar 

Min H-Y, Lee H-Y. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022;54(10):1670–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rubin E, Shan KS, Dalal S, Vu DUD, Milillo-Naraine AM, Guaqueta D, Ergle A. Molecular targeting of the human epidermal growth factor receptor-2 (HER2) genes across various cancers. Int J Mol Sci. 2024;25(2):1064.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaufman NEM, Dhingra S, Jois SD. Vicente MdGH: molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). Molecules. 2021;26(4):1076.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaufman NEM, Dhingra S, Jois SD, Vicente MDGH. Molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). Molecules. 2021;26(4):1076.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodriguez SMB, Kamel A, Ciubotaru GV, Onose G, Sevastre AS, Sfredel V, Danoiu S, Dricu A, Tataranu LG. An overview of EGFR mechanisms and their implications in targeted therapies for glioblastoma. Int J Mol Sci. 2023;24(13):11110.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacobi N, Seeboeck R, Hofmann E, Eger A. ErbB family signalling: a paradigm for oncogene addiction and personalized oncology. Cancers. 2017;9(4):33.

Article  PubMed  PubMed Central  Google Scholar 

Mariam Raju R, Joy AJ, Nulgumnalli Manjunathaiah R, Justin A, Prashantha Kumar BR. EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: a critical review. Res Chem. 2024;7:101490.

CAS  Google Scholar 

Wang D, Liu G, Meng Y, Chen H, Ye Z, Jing J. The configuration of GRB2 in protein interaction and signal transduction. Biomolecules. 2024;14(3):259.

Article  PubMed  PubMed Central  Google Scholar 

Pandey D, Chauhan SC, Kashyap VK, Roy KK. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers. Eur J Med Chem. 2024;277:116771.

Article  CAS  PubMed  Google Scholar 

Kapoor A, Travesset A. Differential dynamics of RAS isoforms in GDP-and GTP-bound states. Proteins Struct Funct Bioinf. 2015;83(6):1091–106.

Article  CAS  Google Scholar 

Nan X, Collisson EA, Lewis S, Huang J, Tamgüney TM, Liphardt JT, McCormick F, Gray JW, Chu S. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci. 2013;110(46):18519–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Freeman AK, Ritt DA, Morrison DK. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell. 2013;49(4):751–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinez Fiesco JA, Durrant DE, Morrison DK, Zhang P. Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding. Nat Commun. 2022;13(1):486.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zenonos K, Kyprianou K. RAS signaling pathways, mutations and their role in colorectal cancer. World J Gastroint Oncol. 2013;5(5):97.

Article  Google Scholar 

Huang R, Dai Q, Yang R, Duan Y, Zhao Q, Haybaeck J, Yang Z. A review: PI3K/AKT/mTOR signaling pathway and its regulated eukaryotic translation initiation factors may be a potential therapeutic target in esophageal squamous cell carcinoma. Front Oncol. 2022;12:817916.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13(1):113.

Article  PubMed  PubMed Central  Google Scholar 

Rowe LR, Bentz BG, Bentz JS. Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J Clin Pathol. 2007;60(11):1211–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niault TS, Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis. 2010;31(7):1165–74.

Article  CAS  PubMed  Google Scholar 

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239–46.

Article  PubMed  Google Scholar 

Santonastaso C, Di Paolo M, Tommaselli A, Morelli L, Pugliese S, Troisi A, Muto T, Di Martino S. A simple and high sensitive method for detection of B-RAF 1799T> A (V600E) mutation in the thyroid fine needle aspirate. World Cancer Res J. 2019;6:e1291.

Google Scholar 

Zablocka T, Kreismane M, Pjanova D, Isajevs S. Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma. Oncol Lett. 2023;25(1):1–9.

Google Scholar 

Macerola E, Poma AM, Vignali P, Basolo A, Ugolini C, Torregrossa L, Santini F, Basolo F. Molecular genetics of follicular-derived thyroid cancer. Cancers. 2021;13(5):1139.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Monaco A, Faioli D, Di Paolo M, Catapano O, D’Orta A, Del Buono M, Del Buono R, Di Francia R. Pharmacogenomics markers for prediction response and toxicity in cancer therapy. WCRJ. 2014;1(3):e276.

Google Scholar 

Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875–85.

Article  CAS  PubMed  Google Scholar 

Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Investig. 2016;126(3):1052–66.

Article  PubMed  PubMed Central